Supplementary Figure S3 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)

Partial dependence plots (PDPs) for (A) Model 4, analysis set 2 (clinical and radiomics); (B) Model 7, analysis set 3 (clinical and genomics); (C) Model 19, analysis set 6 (clinical and genomics, non-squamous patients only). The PDPs show the predicted CATE against the selected feature, by averaging the model's predictions over all patients with that feature set to a specific value and all other features held constant.

Panel A shows PDPs for the top 5 features in Figure 3A, panel 3. Panel B shows PDPs for the top 5 features in Figure 3B, panel 3. Panel C shows PDPs for the top 5 features in Figure 3C, panel 3.</p>